We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+7.22%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$75.4M
AUM Growth
+$9.11M
Cap. Flow
+$14M
Cap. Flow %
18.52%
Top 10 Hldgs %
97.28%
Holding
19
New
2
Increased
–
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.6M
2
LPCN icon
Lipocine
LPCN
+$96K

Top Sells

Rank Stock Value
1
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$2.25M
2
AIXC
AIxCrypto Holdings Inc
AIXC
+$1.14M
3
NTRP
Neurotrope, Inc. Common
NTRP
+$867K
4
FOLD
Amicus Therapeutics
FOLD
+$357K
5
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$96.3K

Sector Composition

Rank Sector Weight
1 Healthcare 99.51%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
1
Corbus Pharmaceuticals
CRBP
$170M
$23.6M 31.23%
124,631
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$20.2M 26.75%
+807,224
New +$18.6M
ABEO icon
3
Abeona Therapeutics
ABEO
$345M
$15.1M 20.02%
94,391
– –
AVXL icon
4
Anavex Life Sciences
AVXL
$222M
$3.85M 5.11%
724,205
– –
NTBL
5
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$3.83M 5.08%
24,589
– –
VNRX icon
6
VolitionRx Ltd
VNRX
$12M
$1.62M 2.15%
23,077
– –
KERX
7
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.45M 1.92%
200,000
– –
ARCT icon
8
Arcturus Therapeutics
ARCT
$157M
$1.35M 1.79%
172,214
– –
AMPE
9
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$1.35M 1.79%
8,652
-476
-5% -$96.3K
SMMT icon
10
Summit Therapeutics
SMMT
$10.6B
$1.1M 1.46%
100,000
– –
ALDX icon
11
Aldeyra Therapeutics
ALDX
$91.7M
$583K 0.77%
124,096
– –
LSTA icon
12
Lisata Therapeutics
LSTA
$15.2M
$549K 0.73%
7,864
– –
EVOK
13
DELISTED
Evoke Pharma
EVOK
$448K 0.59%
1,215
– –
ADXSW
14
DELISTED
Advaxis Inc Warrants
ADXSW
$368K 0.49%
112,500
– –
LPCN icon
15
Lipocine
LPCN
$17.1M
$101K 0.13%
+1,471
New +$96K
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
– –
-50,000
Closed -$357K
AIXC
17
AIxCrypto Holdings Inc
AIXC
$16.6M
– –
-6
Closed -$1.14M
LUMO
18
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-10,393
Closed -$2.25M
NTRP
19
DELISTED
Neurotrope, Inc. Common
NTRP
– –
-45,388
Closed -$867K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Knoll Capital Management held 19 positions worth $75.4M, up 14% from $66.3M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Knoll Capital Management deployed $14M of net new capital in Q2 2017, opening 2 new positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 807,224 shares worth $20.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ampio Pharmaceuticals Inc., an estimated $96.3K trimmed.

  • Knoll Capital Management's largest Q2 2017 buy was Biohaven Pharmaceutical Holding Company Ltd.: 807,224 shares worth $20.2M.
  • Knoll Capital Management's biggest Q2 2017 reduction was Ampio Pharmaceuticals Inc., cutting an estimated $96.3K.
  • Knoll Capital Management fully exited Lumos Pharma, Inc. Common Stock in Q2 2017, selling an estimated $2.25M.
  • Knoll Capital Management's ten largest holdings make up 97% of its $75.4M portfolio in Q2 2017.
  • Knoll Capital Management opened 2 new positions and closed 4 in Q2 2017.
  • Knoll Capital Management's portfolio value rose 14% quarter-over-quarter to $75.4M.

Based on Knoll Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.